文献速递妇科

每周紫杉醇联合溶瘤呼肠孤病毒(Reolysin®)对比每周紫杉醇单药治疗复发性卵巢癌、输卵管癌或腹膜癌的随机IIB期评估:NRG肿瘤学/妇科肿瘤学组研究

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
PubMed 文献 · Gynecol Oncol · 2017-07-27

本研究为NRG肿瘤学/妇科肿瘤学组随机IIB期试验,纳入108例复发性或持续性上皮性卵巢癌、输卵管癌或原发腹膜癌患者,随机接受每周紫杉醇单药或联合溶瘤呼肠孤病毒治疗。主要终点无进展生存期(PFS)在两组间无显著差异(中位4.3个月 vs 4.4个月,HR 1.11,90% CI 0.78-1.59,单侧P=0.687)。联合组严重中性粒细胞减少和严重呼吸不良事件更常见。结论认为联合治疗未能充分降低进展或死亡风险,不值得进一步研究。

要点

  • 联合溶瘤呼肠孤病毒未显著延长复发性卵巢癌患者的PFS(中位4.3 vs 4.4个月)。
  • 联合组严重中性粒细胞减少(12% vs 0%)和严重呼吸不良事件(25% vs 2%)更常见。
  • 无治疗相关死亡,但联合方案未达到进一步研究的阈值。

核心结论

  • 在每周紫杉醇基础上加用溶瘤呼肠孤病毒治疗复发性或持续性卵巢癌、输卵管癌或腹膜癌,未能充分降低进展或死亡风险,不值得进一步研究。

研究设计与样本

  • 随机IIB期试验,纳入108例复发性或持续性上皮性卵巢癌、输卵管癌或腹膜癌患者,可测量或可检测病灶,既往方案不超过3个。
  • 随机分配至紫杉醇单药组(80mg/m2静脉注射,第1、8、15天,每4周重复)或联合组(紫杉醇80mg/m2静脉注射第1、8、15天+呼肠孤病毒3×10^10 TCID50/天静脉注射第1-5天,每4周重复),直至疾病进展或毒性。
  • 主要终点为PFS,设计把握度80%,单侧显著性水平10%,检测风险比降低37.5%。
  • 108例入组,其中100例可评估毒性。

主要发现

  • 中位PFS:紫杉醇单药组4.3个月 vs 联合组4.4个月(HR 1.11,90%双侧CI 0.78-1.59,单侧P=0.687)。
  • 客观缓解率:紫杉醇单药组45例可测量病灶患者中20% vs 联合组46例中17.4%(渐近相对缓解概率0.87,90% CI 0.42-1.79)。
  • 严重不良事件:联合组严重中性粒细胞减少(≥4级)12% vs 紫杉醇组0%;严重呼吸不良事件(≥3级)25% vs 2%。
  • 无治疗相关死亡。

临床怎么用

  • 原文结论认为,在每周紫杉醇基础上加用呼肠孤病毒未能充分降低进展或死亡风险,不值得进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS: Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80mg/m2 intravenously days 1, 8, and 15 every 4weeks) or the combination of paclitaxel (80mg/m2 intravenously days 1, 8, and 15) plus reovirus 3×1010TCID50/day intravenously on days 1-5, both every 4weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%. RESULTS: The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3months for paclitaxel and 4.4months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P=0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade≥4, 12% versus 0%), and severe respiratory adverse events (grade≥3, 25% versus 2%). No deaths were considered treatment related. CONCLUSION: The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cohn DE, Sill MW, Walker JL, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017. PMID: 28756871. doi:10.1016/j.ygyno.2017.07.135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。